CoChat
Sign Up
Cited by 124Frailty in Older AdultsCancer survivorship and careNutrition and Health in Aging

Frailty and aging in cancer survivors

Open access
Ness, Kirsten K., Wogksch, Matthew D.·2020·Translational Research
DOI 10.1016/j.trsl.2020.03.013PMC PMC7321876
Open this paper in CoChat — free account

Abstract

There are over 15 million survivors of cancer in the United States whose rates of frailty, an aging phenotype, range from just under 10% to over 80%. Frailty impacts not only disease survival but also long-term function and quality of life in children, adolescents, and in all adults diagnosed and/or treated for cancer. This review explains frailty as a construct and model of physiologic well-being. It also describes how frailty at diagnosis impacts cancer outcomes in adult populations and enumerates the prevalence of frailty in different populations of cancer survivors. Biological mechanisms responsible for aging and potentially for frailty among individuals with or who have been treated for cancer are discussed. Finally, promising pharmaceutical and lifestyle interventions designed to impact aging rather than a specific disease, tested in other populations, but likely applicable in cancer patients and survivors, are discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.trsl.2020.03.013

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TIS is believed to be a major driving force of frailty and other AEs in adults owing to its detrimental effect on tissue function via chronic inflammation, similar to 'inflammaging'.

    “As in children and adolescents, TIS is also believed to be a major driving force of frailty and other AEs in adults owing to its detrimental effect on tissue function via chronic inflammation, similar to 'inflammaging' , which is a chronic mild inflammatory process that develops with age 198,200,201 .”

    From Senescence and cancer — role and therapeutic opportunities (2022) · cites this paper as [200]

    The Introduction’s ‘Potential biological mechanisms for frailty among survivors’ section links cancer treatment to cellular senescence and reports senescence-associated inflammatory markers in adult cancer survivors. It also describes chronic inflammation as harmful to tissue function. It does not identify therapy-induced senescence as a major driving force of frailty and other adverse events in adults generally; the discussion is framed around possible mechanisms in cancer survivors. The indexed passages provide no page numbers. (LLM, conf=0.83)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 100

  1. [2]Guy GP Jr, Yabroff KR, Ekwueme DU, Rim SH, Li R, Richardson LC. Economic Burden of Chronic Conditions Among Survivors of Cancer in the United States. J Clin Oncol. 2017; 35: 2053– 61. 28471724 PMC6059377
  2. [3]Guida JL, Ahles TA, Belsky D, Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors. J Natl Cancer Inst. 2019; 111: 1245– 54. 31321426 PMC7962788
  3. [4]Hoogendijk EO, Afilalo J, Ensrud KE, Frailty: implications for clinical practice and public health. Lancet. 2019; 394: 1365– 75. 31609228
  4. [5]Fried LP, Tangen CM, Walston J, Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001; 56: M146– 56. 11253156
  5. [6]Bandeen-Roche K, Xue QL, Ferrucci L, Phenotype of frailty: characterization in the women’s health and aging studies. J Gerontol A Biol Sci Med Sci. 2006; 61: 262– 6. 16567375
  6. [8]Woods NF, LaCroix AZ, Gray SL, Frailty: emergence and consequences in women aged 65 and older in the Women’s Health Initiative Observational Study. J Am Geriatr Soc. 2005; 53: 1321– 30. 16078957
  7. [10]Ensrud KE, Ewing SK, Taylor BC, Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med. 2008; 168: 382– 9. 18299493
  8. [11]Forti P, Rietti E, Pisacane N, A comparison of frailty indexes for prediction of adverse health outcomes in an elderly cohort. Arch Gerontol Geriatr. 2012; 54: 16– 20. 21339007
  9. [12]Freiheit EA, Hogan DB, Eliasziw M, Development of a frailty index for patients with coronary artery disease. J Am Geriatr Soc. 2010; 58: 1526– 31. 20633198
  10. [13]Klein BE, Klein R, Knudtson MD, Lee KE. Frailty, morbidity and survival. Arch Gerontol Geriatr. 2005; 41: 141– 9. 16085065
  11. [14]Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007; 62: 722– 7. 17634318
  12. [16]Collard RM, Boter H, Schoevers RA, Oude Voshaar RC. Prevalence of frailty in community-dwelling older persons: a systematic review. J Am Geriatr Soc. 2012; 60: 1487– 92. 22881367
  13. [17]Handforth C, Clegg A, Young C, The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol. 2015; 26: 1091– 101. 25403592
  14. [18]de Souto Barreto P One operational definition by population: the need for local evaluations of frailty. J Physiol Anthropol. 2011; 30: 259– 62. 22197959
  15. [19]Shahrokni A, Tin A, Alexander K, Development and Evaluation of a New Frailty Index for Older Surgical Patients With Cancer. JAMA Netw Open. 2019; 2:e193545. PMC6512296 31074814
  16. [20]Franco I, Chen YH, Chipidza F, Use of frailty to predict survival in elderly patients with early stage non-small-cell lung cancer treated with stereotactic body radiation therapy. J Geriatr Oncol. 2018; 9: 130– 7. 28941581
  17. [21]Pamoukdjian F, Levy V, Sebbane G, Slow Gait Speed Is an Independent Predictor of Early Death in Older Cancer Outpatients: Results from a Prospective Cohort Study. J Nutr Health Aging. 2017; 21: 202– 6. 28112777
  18. [22]Williams GR, Dunham L, Chang Y, Geriatric Assessment Predicts Hospitalization Frequency and Long-Term Care Use in Older Adult Cancer Survivors. J Oncol Pract. 2019; 15: e399– e409. 30870086 PMC7846045
  19. [23]Mandelblatt JS, Small BJ, Luta G, Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. J Clin Oncol. 2018:JCO1800140. PMC7237199 30281396
  20. [24]Mandelblatt JS, Clapp JD, Luta G, Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance). Cancer. 2016; 122: 3555– 63. 27447359 PMC5113662
  21. [25]Ness KK, Krull KR, Jones KE, Physiologic frailty as a sign of accelerated aging among adult survivors of childhood cancer: a report from the St Jude Lifetime cohort study. J Clin Oncol. 2013; 31: 4496– 503. 24248696 PMC3871511
  22. [26]Degesys N, Klein C, Binner M, Browner I, Shapiro G. Fitness screening in older cancer patients. J Am Geriatr Soc. 2011; 59: S141.
  23. [27]Chemaitilly W, Li Z, Krasin MJ, Premature Ovarian Insufficiency in Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort. J Clin Endocrinol Metab. 2017; 102: 2242– 50. 28368472 PMC5505200
  24. [28]Eissa HM, Lu L, Baassiri M, Chronic disease burden and frailty in survivors of childhood HSCT: a report from the St. Jude Lifetime Cohort Study. Blood Adv. 2017; 1: 2243– 6. 29296872 PMC5737129
  25. [29]Hayek S, Gibson TM, Leisenring WM, Prevalence and Predictors of Frailty in Childhood Cancer Survivors and Siblings: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2019:Jco1901226. PMC6968796 31800343
  26. [30]van Iersel L, Li Z, Srivastava DK, Hypothalamic-Pituitary Disorders in Childhood Cancer Survivors: Prevalence, Risk Factors and Long-Term Health Outcomes. J Clin Endocrinol Metab. 2019; 104: 6101– 15. 31373627 PMC7296130
  27. [31]Vatanen A, Hou M, Huang T, Clinical and biological markers of premature aging after autologous SCT in childhood cancer. Bone Marrow Transplant. 2017; 52: 600– 5. 28067869
  28. [32]Wilson CL, Chemaitilly W, Jones KE, Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 2016; 34: 2509– 15. 27001572 PMC4962734
  29. [33]Arora M, Sun CL, Ness KK, Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients: Results From the Bone Marrow Transplant Survivor Study. JAMA Oncol. 2016; 2: 1277– 86. 27254472 PMC5078990
  30. [34]Bennett JA, Winters-Stone KM, Dobek J, Nail LM. Frailty in older breast cancer survivors: age, prevalence, and associated factors. Oncol Nurs Forum. 2013; 40: E126– 34. 23615146 PMC3988495
  31. [35]Brown JC, Harhay MO, Harhay MN. The Prognostic Importance of Frailty in Cancer Survivors. J Am Geriatr Soc. 2015; 63: 2538– 43. 26566767 PMC4688177
  32. [36]Bylow K, Hemmerich J, Mohile SG, Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology. 2011; 77: 934– 40. 21269665 PMC3074039
  33. [37]Johnson MS, Bailey TL, Schmid KK, Lydiatt WM, Johanning JM. A frailty index identifies patients at high risk of mortality after tracheostomy. Otolaryngol Head Neck Surg. 2014; 150: 568– 73. 24436464
  34. [38]Moore JX, Akinyemiju T, Bartolucci A, Mediating Effects of Frailty Indicators on the Risk of Sepsis After Cancer. J Intensive Care Med. 2018:885066618779941. PMC6026551 29862879
  35. [39]Ronning B, Wyller TB, Jordhoy MS, Frailty indicators and functional status in older patients after colorectal cancer surgery. J Geriatr Oncol. 2014; 5: 26– 32. 24484715
  36. [40]Winters-Stone KM, Moe E, Graff JN, Falls and Frailty in Prostate Cancer Survivors: Current, Past, and Never Users of Androgen Deprivation Therapy. J Am Geriatr Soc. 2017; 65: 1414– 9. 28263373 PMC5507739
  37. [41]Phung LA, Karvinen SM, Colson BA, Thomas DD, Lowe DA. Age affects myosin relaxation states in skeletal muscle fibers of female but not male mice. PLoS One. 2018; 13:e0199062. PMC6143227 30226869
  38. [43]Smitherman AB, Anderson C, Lund JL, Frailty and Comorbidities Among Survivors of Adolescent and Young Adult Cancer: A Cross-Sectional Examination of a Hospital-Based Survivorship Cohort. J Adolesc Young Adult Oncol. 2018; 7: 374– 83. 29570988 PMC5994155
  39. [44]Lee SJ, Park YJ, Cartmell KB. Sarcopenia in cancer survivors is associated with increased cardiovascular disease risk. Support Care Cancer. 2018; 26: 2313– 21. 29411130
  40. [45]Villasenor A, Ballard-Barbash R, Baumgartner K, Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv. 2012; 6: 398– 406. 23054848 PMC3747827
  41. [46]Lee SJ, Kim NC. Association Between Sarcopenia and Metabolic Syndrome in Cancer Survivors. Cancer Nurs. 2017; 40: 479– 87. 27922919
  42. [47]Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013; 153: 1194– 217. 23746838 PMC3836174
  43. [48]Maccormick RE. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses. 2006; 67: 212– 5. 16546325
  44. [49]Dato S, Soerensen M, Rose G. Untangling the Genetics of Human Longevity-A Challenging Quest. Genes (Basel). 2019; 10. PMC6722970 31370355
  45. [50]Boldrin E, Rumiato E, Fassan M, Genetic risk of subsequent esophageal cancer in lymphoma and breast cancer long-term survival patients: a pilot study. Pharmacogenomics J. 2016; 16: 266– 71. 26054330
  46. [51]Hildebrandt MAT, Reyes M, Wu X, Hypertension Susceptibility Loci are Associated with Anthracycline-related Cardiotoxicity in Long-term Childhood Cancer Survivors. Sci Rep. 2017; 7: 9698. 28851949 PMC5575079
  47. [52]Krajinovic M, Elbared J, Drouin S, Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016; 16: 530– 5. 26345518
  48. [53]Nadeau G, Ouimet-Grennan E, Aaron M, Identification of genetic variants associated with skeletal muscle function deficit in childhood acute lymphoblastic leukemia survivors. Pharmgenomics Pers Med. 2019; 12: 33– 45. 31114288 PMC6489684
  49. [54]Rajic V, Aplenc R, Debeljak M, Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma. 2009; 50: 1693– 8. 19863340
  50. [55]Richard MA, Lupo PJ, Morton LM, Genetic variation in POT1 and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. PLoS One. 2020; 15:e0228887. PMC7010302 32040538
  51. [56]Schack LMH, Petersen SE, Nielsen S, Validation of genetic predictors of late radiation-induced morbidity in prostate cancer patients. Acta Oncol. 2017; 56: 1514– 21. 28844157
  52. [57]van der Kooi ALF, Clemens E, Broer L, Genetic variation in gonadal impairment in female survivors of childhood cancer: a PanCareLIFE study protocol. BMC Cancer. 2018; 18: 930. 30257669 PMC6158859
  53. [58]van Dorp W, van den Heuvel-Eibrink MM, Stolk L, Genetic variation may modify ovarian reserve in female childhood cancer survivors. Hum Reprod. 2013; 28: 1069– 76. 23360674
  54. [59]Frias S, Ramos S, Salas C, Nonclonal Chromosome Aberrations and Genome Chaos in Somatic and Germ Cells from Patients and Survivors of Hodgkin Lymphoma. Genes (Basel). 2019; 10. PMC6357137 30634664
  55. [60]Bilban-Jakopin C, Bilban M. Genotoxic effects of radiotherapy and chemotherapy on circulating lymphocytes in patients with Hodgkin’s disease. Mutat Res. 2001; 497: 81– 8. 11525910
  56. [61]M’Kacher R, Girinsky T, Koscielny S, Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin’s lymphoma patients. Int J Radiat Oncol Biol Phys. 2003; 57: 321– 6. 12957241
  57. [62]Salas C, Niembro A, Lozano V, Persistent genomic instability in peripheral blood lymphocytes from Hodgkin lymphoma survivors. Environ Mol Mutagen. 2012; 53: 271– 80. 22434555
  58. [63]Smith LM, Evans JW, Mori M, Brown JM. The frequency of translocations after treatment for Hodgkin’s disease. Int J Radiat Oncol Biol Phys. 1992; 24: 737– 42. 1429098
  59. [64]Ariffin H, Azanan MS, Abd Ghafar SS, Young adult survivors of childhood acute lymphoblastic leukemia show evidence of chronic inflammation and cellular aging. Cancer. 2017; 123: 4207– 14. 28654149
  60. [65]Song N, Li Z, Qin N, Shortened Leukocyte Telomere Length Associates with an Increased Prevalence of Chronic Health Conditions among Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort. Clin Cancer Res. 2020. PMC7231652 31969337
  61. [66]Wang J, Van Den Berg D, Hwang AE, DNA methylation patterns of adult survivors of adolescent/young adult Hodgkin lymphoma compared to their unaffected monozygotic twin. Leuk Lymphoma. 2019; 60: 1429– 37. 30668190 PMC7781082
  62. [67]Daniel S, Nylander V, Ingerslev LR, T cell epigenetic remodeling and accelerated epigenetic aging are linked to long-term immune alterations in childhood cancer survivors. Clin Epigenetics. 2018; 10: 138. 30400990 PMC6219017
  63. [68]Lupo PJ, Brown AL, Arroyo VM, DNA methylation and obesity in survivors of pediatric acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Genes Chromosomes Cancer. 2019; 58: 52– 9. 30382603 PMC6295278
  64. [69]Leahy J, Spahis S, Bonneil E, Insight from mitochondrial functions and proteomics to understand cardiometabolic disorders in survivors of acute lymphoblastic leukemia. Metabolism. 2018; 85: 151– 60. 29563052
  65. [70]Chemaitilly W, Cohen LE, Mostoufi-Moab S, Endocrine Late Effects in Childhood Cancer Survivors. J Clin Oncol. 2018; 36: 2153– 9. 29874130
  66. [71]Mostoufi-Moab S, Seidel K, Leisenring WM, Endocrine Abnormalities in Aging Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study. J Clin Oncol. 2016; 34: 3240– 7. 27382091 PMC5024546
  67. [72]DeFilipp Z, Duarte RF, Snowden JA, Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT. Bone Marrow Transplant. 2017; 52: 173– 82. 27548466 PMC5288134
  68. [73]Coughlin SS, Smith SA. The Insulin-like Growth Factor Axis, Adipokines, Physical Activity, and Obesity in Relation to Breast Cancer Incidence and Recurrence. Cancer Clin Oncol. 2015; 4: 24– 31. 26251693 PMC4524449
  69. [74]Calip GS, Malone KE, Gralow JR, Metabolic syndrome and outcomes following early-stage breast cancer. Breast Cancer Res Treat. 2014; 148: 363– 77. 25301086 PMC4236717
  70. [75]Ruiz-Pinto S, Pita G, Martin M, Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. Breast Cancer Res Treat. 2018; 167: 249– 56. 28913729
  71. [76]Lipshultz SE, Anderson LM, Miller TL, Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016; 122: 946– 53. 26762648 PMC4777628
  72. [78]Alfano CM, Peng J, Andridge RR, Inflammatory Cytokines and Comorbidity Development in Breast Cancer Survivors Versus Noncancer Controls: Evidence for Accelerated Aging? J Clin Oncol 2017; 35: 149– 56. 27893337 PMC5455675
  73. [79]Marcoux S, Le ON, Langlois-Pelletier C, Expression of the senescence marker p16INK4a in skin biopsies of acute lymphoblastic leukemia survivors: a pilot study. Radiat Oncol. 2013; 8: 252. 24171943 PMC3827993
  74. [80]Wood WA, Krishnamurthy J, Mitin N, Chemotherapy and Stem Cell Transplantation Increase p16(INK4a) Expression, a Biomarker of T-cell Aging. EBioMedicine. 2016; 11: 227– 38. 27591832 PMC5049997
  75. [81]Lewis NL, Mullaney M, Mangan KF, Measurable immune dysfunction and telomere attrition in long-term allogeneic transplant recipients. Bone Marrow Transplant. 2004; 33: 71– 8. 14704659
  76. [82]Walter KR, Ford ME, Gregoski MJ, Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat. 2019; 173: 559– 71. 30368741 PMC6394600
  77. [83]Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001; 44: 129– 46. 11270668
  78. [84]Ferrucci L, Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol. 2018; 15: 505– 22. 30065258 PMC6146930
  79. [85]Zhang X, Meng X, Chen Y, Leng SX, Zhang H. The Biology of Aging and Cancer: Frailty, Inflammation, and Immunity. Cancer J 2017; 23: 201– 5. 28731941
  80. [86]Lacourt TE, Heijnen CJ. Mechanisms of Neurotoxic Symptoms as a Result of Breast Cancer and Its Treatment: Considerations on the Contribution of Stress, Inflammation, and Cellular Bioenergetics. Curr Breast Cancer Rep. 2017; 9: 70– 81. 28616125 PMC5445149
  81. [87]Kraig E, Linehan LA, Liang H, A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. Exp Gerontol. 2018; 105: 53– 69. 29408453 PMC5869166
  82. [89]Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. Mol Nutr Food Res. 2015; 59: 147– 59. 25138371
  83. [90]McCubrey JA, Lertpiriyapong K, Steelman LS, Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY). 2017; 9: 1477– 536. 28611316 PMC5509453
  84. [91]Baksi A, Kraydashenko O, Zalevkaya A, A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. Br J Clin Pharmacol. 2014; 78: 69– 77. 24446723 PMC4168381
  85. [92]Libri V, Brown AP, Gambarota G, A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS One. 2012; 7:e51395. PMC3527451 23284689
  86. [93]Venkatasubramanian S, Noh RM, Daga S, Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc. 2013; 2:e000042. PMC3698759 23770971
  87. [94]Martens CR, Denman BA, Mazzo MR, Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults. Nat Commun. 2018; 9: 1286. 29599478 PMC5876407
  88. [98]Burstein AH, Grimes I, Galasko DR, Effect of TTP488 in patients with mild to moderate Alzheimer’s disease. BMC Neurol. 2014; 14: 12. 24423155 PMC4021072
  89. [99]Galasko D, Bell J, Mancuso JY, Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology. 2014; 82: 1536– 42. 24696507 PMC4011464
  90. [100]Sabbagh MN, Agro A, Bell J, PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord. 2011; 25: 206– 12. 21192237 PMC3346183
  91. [101]Daum CW, Cochrane SK, Fitzgerald JD, Johnson L, Buford TW. Exercise Interventions for Preserving Physical Function Among Cancer Survivors in Middle to Late Life. J Frailty Aging. 2016; 5: 214– 24. 27883168
  92. [102]Negm AM, Kennedy CC, Thabane L, Management of Frailty: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials. J Am Med Dir Assoc. 2019; 20: 1190– 8. 31564464
  93. [105]Ornish D, Lin J, Chan JM, Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study. Lancet Oncol. 2013; 14: 1112– 20. 24051140
  94. [106]Sanft T, Usiskin I, Harrigan M, Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. Breast Cancer Res Treat. 2018; 172: 105– 12. 30062572
  95. [107]Delgado-Cruzata L, Zhang W, McDonald JA, Dietary modifications, weight loss, and changes in metabolic markers affect global DNA methylation in Hispanic, African American, and Afro-Caribbean breast cancer survivors. J Nutr. 2015; 145: 783– 90. 25833781 PMC4381766
  96. [108]Greenlee H, Ogden Gaffney A, Aycinena AC, Long-term Diet and Biomarker Changes after a Short-term Intervention among Hispanic Breast Cancer Survivors: The ¡Cocinar Para Su Salud! Randomized Controlled Trial. Cancer Epidemiol Biomarkers Prev. 2016; 25: 1491– 502. 27461049 PMC5501703
  97. [109]Saxton JM, Scott EJ, Daley AJ, Effects of an exercise and hypocaloric healthy eating intervention on indices of psychological health status, hypothalamic-pituitary-adrenal axis regulation and immune function after early-stage breast cancer: a randomised controlled trial. Breast Cancer Res. 2014; 16: R39. 24731917 PMC4052984
  98. [110]Baxter BA, Oppel RC, Ryan EP. Navy Beans Impact the Stool Metabolome and Metabolic Pathways for Colon Health in Cancer Survivors. Nutrients. 2018; 11. PMC6356708 30583518
  99. [111]Harrigan M, Cartmel B, Loftfield E, Randomized Trial Comparing Telephone Versus In-Person Weight Loss Counseling on Body Composition and Circulating Biomarkers in Women Treated for Breast Cancer: The Lifestyle, Exercise, and Nutrition (LEAN) Study. J Clin Oncol. 2016; 34: 669– 76. 26598750 PMC4872022
  100. [112]Kober KM, Mazor M, Abrams G, Phenotypic Characterization of Paclitaxel-Induced Peripheral Neuropathy in Cancer Survivors. J Pain Symptom Manage. 2018; 56: 908– 19 e3. 30172061 PMC6289693

Cited by

Sorted by citations

Authors
Ness, K. K., & Wogksch, M. D.
Affiliations
St. Jude Children's Research Hospital (US)
Corresponding author
Ness, Kirsten K.
ORCID
Venue
Translational Research
Publisher
Elsevier BV
Published
2020-07
Volume
221
Pages
65-82
ISSN
  • 1878-1810 (ISSN-L)
  • 1931-5244
DOI
10.1016/j.trsl.2020.03.013
PMC
PMC7321876
OpenAlex
W3022646403
Cited by
124
References
11
Citations by year
2026: 18 · 2025: 27 · 2024: 28 · 2023: 28 · 2022: 15 · 2021: 7 · 2020: 1
FWCI
1.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Translational research (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (P30CA021765)
  • American Lebanese Syrian Associated Charities
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Frailty in Older Adults
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
Keywords
frailty, cancer survivors, aging, Fried frailty phenotype, oncological outcomes, quality of life, frailty interventions, lifestyle intervention, children and adolescents with cancer
MeSH terms
Cancer Survivors, Frailty, Aging, Humans, Neoplasms, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review